Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

References

• Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914. doi:10.1183/13993003.01914-2018
   PubMed Web of Science ®Google Scholar
• Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–116. doi:10.1016/j.jacc.2013.10.036
   PubMed Web of Science ®Google Scholar
• Barbera JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs. 2009;69(9):1153–1171. doi:10.2165/00003495-200969090-00002
   PubMed Web of Science ®Google Scholar
• Blanco I, Piccari L, Barbera JA. Pulmonary vasculature in COPD: the silent component. Respirology. 2016;21(6):984–994. doi:10.1111/resp.12772
   PubMed Web of Science ®Google Scholar
• Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31(4):373–380. doi:10.1016/j.healun.2011.11.020
   PubMed Web of Science ®Google Scholar
• Samareh Fekri M, Torabi M, Azizi Shoul S, Mirzaee M. Prevalence and predictors associated with severe pulmonary hypertension in COPD. Am J Emerg Med. 2018;36(2):277–280. doi:10.1016/j.ajem.2017.08.014
   PubMed Web of Science ®Google Scholar
• Andre P, Joshi SR, Briscoe SD, Alexander MJ, Li G, Kumar R. Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-β superfamily signaling. Front Med. 2022;8:814222. doi:10.3389/fmed.2021.814222
   Web of Science ®Google Scholar
• Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med. 1988;66(249):65–85.
   PubMedGoogle Scholar
• Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: national Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–124. doi:10.1007/BF00175982
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–975. doi:10.1183/13993003.01032-2015
   PubMed Web of Science ®Google Scholar
• Harder EM, Waxman AB. Clinical trials in group 3 pulmonary hypertension. Curr Opin Pulm Med. 2020;26(5):391–396. doi:10.1097/MCP.0000000000000694
   PubMed Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603–614. doi:10.1038/nrcardio.2017.84
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2(4):293–300. doi:10.1016/S2213-2600(14)70013-X
   PubMed Web of Science ®Google Scholar
• Vitulo P, Stanziola A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2017;36(2):166–174.
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012;9(3):268–275. doi:10.3109/15412555.2011.651180
   PubMedGoogle Scholar
• Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–628. doi:10.1183/09031936.00011308
   PubMed Web of Science ®Google Scholar
• Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81(1):533–559. doi:10.1146/annurev-biochem-050410-100030
   PubMedGoogle Scholar
• Weissmann N, Lobo B, Pichl A, et al. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med. 2014;189(11):1359–1373. doi:10.1164/rccm.201311-2037OC
   PubMed Web of Science ®Google Scholar
• Seimetz M, Parajuli N, Pichl A, et al. Cigarette smoke-induced emphysema and pulmonary hypertension can be prevented by phosphodiesterase 4 and 5 inhibition in mice. PLoS One. 2015;10(6):e0129327. doi:10.1371/journal.pone.0129327
   PubMed Web of Science ®Google Scholar
• Arif R, Pandey A, Zhao Y, Arsenault-Mehta K, Khoujah D, Mehta S. Treatment of pulmonary hypertension associated with COPD: a systematic review. ERJ Open Res. 2022;8(1):00348–2021. doi:10.1183/23120541.00348-2021
   PubMedGoogle Scholar
• Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7(9):780–790.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–D41. doi:10.1016/j.jacc.2013.10.029
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):535–541. doi:10.1164/ajrccm.160.2.9811062
   PubMed Web of Science ®Google Scholar
• Bajwa EK, Cislak D, Palcza J, et al. Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023;206:107065. doi:10.1016/j.rmed.2022.107065
   PubMed Web of Science ®Google Scholar
• Gredic M, Blanco I, Kovacs G, et al. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol. 2021;178(1):132–151. doi:10.1111/bph.14979
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. Erratum in: Eur Heart J. 2023;44(15):1312. doi:10.1093/eurheartj/ehac237
   PubMed Web of Science ®Google Scholar